*For medical professionals only
The medical community takes you to see the 2024 AACR
Collation丨AACR reporting group in the medical community
The American Association for Cancer Research (AACR) Annual Meeting is one of the world's longest-running academic conferences for cancer research. The conference focuses on the progress of early cancer research and innovation, and brings together cutting-edge research results in the field of oncology. The 2024 AACR Annual Meeting will be held in San Diego, USA, from April 5 to 10.
Since 2004, AACR has established awards for scientists who have made significant contributions to scientific and technological innovation and progress in the field of anti-cancer, and has established the Lifetime Achievement Award for Cancer Research, which is awarded to scientists who have made outstanding academic achievements and made a lasting impact and profound change in cancer research through their efforts. Who will win this year's awards? Follow the footsteps of the medical community and witness the world's top academic style!
Lifetime Achievement Award for Cancer Research
AACR Lifetime Achievement Award for Cancer Research:
Steven A. Rosenberg，MD，PhD
Award Ceremony: April 6, 15:00 (local time)
Steven A. Rosenberg is a Fellow of the American Society for Cancer Research, a Senior Fellow at the National Cancer Institute (NCI) Center for Cancer Research, Chief of the NCI Division of Surgery, Leader of the Division of Tumor Immunology, and Professor of Surgery at the George Washington University School of Medicine and Health Sciences.
Steven A. Rosenberg has been recognized for his lifelong scientific achievements and tremendous contributions to cancer research and patient care, most notably for his basic and clinical research on IL-2, which led to the approval of this immunotherapy by the U.S. Food and Drug Administration (FDA) for the treatment of patients with metastatic melanoma and kidney cancer. His adoptive immune cell therapy through tumor-infiltrating lymphocytes (TILs) has resulted in durable remissions in patients with advanced solid tumors.
Hematologic malignancies: leukemia and lymphoma
AACR Award for Outstanding Achievement in Hematological Cancer Research:
Owen N. Witte,M.D.
Award Ceremony: April 9, 16:30 (local time)
Owen N. Witte is a Fellow of the AACR College and currently the Chair of Developmental Immunology, University Professor of Microbiology, Immunology and Molecular Genetics and Molecular and Medical Pharmacology, Director Emeritus of the Eli & Edythe Broad Center for Regenerative Medicine and Stem Cell Research, and a member of the UCLA Jonsson Comprehensive Cancer Center. He has made unprecedented contributions to elucidating the role of tyrosine kinases (TKIs) in hematologic malignancies and has played a key role in the development of novel cancer therapeutics.
He was the first to discover the ABL fusion tumor protein in leukemia and predicted that the mutated ABL kinase could be used as a viable drug target, and then developed imatinib as a first-line therapy for chronic myeloid leukemia. Subsequently, Owen N. Witte defined Bruton's tyrosine kinase (BTK) as a key driver of antigen-activated lymphoma and autoimmune disease, a breakthrough discovery that led to the clinical development of the FDA-approved BTK inhibitor ibrutinib for the treatment of B-cell lymphoma.
AACR Distinguished Public Service Award for Lifetime Achievement in Cancer Research:
Franco Cavalli,MD
Award Ceremony: April 7, 16:15 (local time)
Franco Cavalli is President of the Oncology Institute Foundation, Past President of the International Union for Cancer Control, Past President of the Scientific Committee of the European Academy of Oncology and President of the World Oncology Forum. He was recognized for his long-standing scientific achievements in the fields of breast cancer, leukemia and lymphoma, as well as clinical studies involving VP16 and contributions to the development of therapeutics such as cisplatin, carboplatin and paclitaxel. In addition, he has demonstrated leadership and vision in improving global cancer research and health through novel and innovative mechanisms, including ICML, the world's top biennial conference on lymphoma, which is dedicated to improving pediatric cancer research and treatment in Central America.
Basic research in cancer
AACR Outstanding Achievement Award for Basic Research in Cancer:
Sarah-Maria Magdalene, PhD
Award Ceremony: April 8, 17:30 (local time)
Sarah-Maria Fendt is a principal investigator and professor of oncology at the VIB Center for Cancer Biology at the University of Leuven in Belgium. She has made pioneering contributions to deciphering the role of metabolic remodeling during cancer invasion and metastasis, as well as identifying the principles of metabolic regulation that make cancer cells malleable and heterogeneous. Sarah-Maria Fendt described the novel function of phosphoglycerol dehydrogenase (PHGDH) in the process of cancer metastasis and found that the lipid-rich environment promotes metastasis by activating signaling pathways that subsequently drive metastatic cell growth.
AACR-G.H.A. Clowes杰出癌症基础研究奖：
David Pellman, MD
Award Ceremony: April 8, 17:30 (local time)
David Pellman is a Fellow of the American Society for Cancer Research and currently serves as the Margaret M. Dyson Professor of Pediatric Oncology at the Dana-Farber Cancer Institute, Professor of Cell Biology at Harvard Medical School, Fellow at the Howard Hughes Medical Institute, and Associate Director of Basic Sciences at the Harvard Cancer Center.
He has done pioneering work in identifying mechanisms of chromosomal structure and quantitative aberrations in cancer, demonstrating the potential of genome-wide replication, which is now known to occur in approximately 40% of human cancers, to accelerate somatic evolution of cancers through the development of innovative mouse models. Using a self-developed method that combines long-term live-cell imaging with single-cell whole-genome sequencing, his research group has reproduced chromosomal trifissures in the lab, thereby contributing to the mechanistic understanding of cancer genome instability.
AACR-Margaret Foti Award for Leadership and Extraordinary Achievement in Cancer Research:
Chi Van Dang,MD,PhD
Award Ceremony: April 8, 16:45 (local time)
Chi Van Dang is currently the Scientific Director of the Ludwig Cancer Institute, the Bloomberg Distinguished Professor of Cancer Medicine at Johns Hopkins University, the Professor of Oncology and Cell Biology at the Johns Hopkins University School of Medicine, and the Professor of Biochemistry and Molecular Biology at the Johns Hopkins Bloomberg School of Public Health in Baltimore, Maryland.
His research has helped define the complex function of the MYC oncogene (a central switch in human cancer) and identified key domains that mediate its transcription factor activity, further documenting that MYC may disrupt circadian metabolism and is using these concepts to target cancer cell metabolism as a new anti-cancer strategy.
Clinical & Translational Research
AACR-Joseph H. Burchenal Award for Outstanding Achievement in Clinical Cancer Research:
Joseph A. Sparano,MD
Award Ceremony: 7 April, 16:30 (local time)
Joseph A. Sparano is the Ezra M. Greenspan Professor of Clinical Therapeutics in Cancer, Director of the Division of Hematology and Medical Oncology at Icahn School of Medicine at Mount Sinai, and Associate Director of the Tisch Cancer Institute. He has led some of the most impactful and practice-changing research in the field of breast cancer and AIDS-related cancers, uncovered factors that contribute to racial disparities in breast cancer, and advanced cancer treatment and prevention research in vulnerable populations living with HIV.
Among them, the landmark TAILORx clinical trial changed the standard of care for women with early-stage ER-positive, HER2-negative, nodule-negative breast cancer, confirmed the clinical utility of the 21-gene recurrence score assay in guiding adjuvant chemotherapy, and led to the development of the RSClin tool, which aids in making more informed decisions by integrating the prognostic information provided by recurrence scores and clinicopathological factors.
Aaker-Won Ki Hong转化和临床癌症研究杰出成就奖:
Scott Kopetz，MD，PhD
Award Ceremony: 7 April, 16:30 (local time)
The award, supported by the Waun Ki Hong Endowment Fund, recognizes cancer researchers who have demonstrated outstanding achievements in translational and clinical cancer research around the world, and are under the age of 51 at the time of the award.
Scott Kopetz is Professor of Gastrointestinal Medical Oncology and Associate Dean for Translational Integration at the University of Texas MD Anderson Cancer Center in Houston, Texas. He was honored for pioneering the development of novel therapies for patients with metastatic colon cancer with BRAF gene mutations with poor prognosis. Scott Kopetz's clinical study has led to the discovery of KRAS/NRAS mutations that lead to resistance to MAPK pathway inhibition in patients with BRAF-mutated cancers by developing personalized treatment plans based on genetic profiles identified in a patient's xenograft model. This finding makes the combination of BRAF and EGFR inhibitors a standard of care and advances our understanding of the mechanisms of resistance in these patients.
Immunotherapy and targeted therapy
AACR-Lloyd J. Old癌症免疫学奖:
Gordon J. Freeman，PhD
Award Ceremony: April 8, 17:00 (local time)
Gordon J. Freeman is a Fellow of the American Society for Cancer Research and is currently Professor of Medical Oncology at the Dana-Farber Cancer Institute and Harvard Medical School. He has made pioneering contributions to the discovery of the T cell programmed death-1 receptor (PD-1) signaling pathway and the PD-1 ligands PD-L1 and PD-L2, revealing that this pathway is involved in tumor evasion immune surveillance, and demonstrating that blocking this pathway can elicit an anti-tumor immune response. His outstanding research has led to the development of immunotherapies for cancer, autoimmune diseases, and transplant rejection.
AACR Award for Outstanding Achievement in Cancer Research Chemistry:
Nathanael S. Gray，PhD
Award Ceremony: April 8, 17:00 (local time)
Nathanael S. Gray is a Fellow of the American Society for Cancer Research and currently the Krishnan-Shah Family Professor of Chemistry and Systems Biology at Stanford University in California. He has pioneered innovative structure-based chemical biology approaches in the design and development of protein inhibitors and degraders that have revolutionized the future of cancer therapies. He has also pioneered the development of multiple cancer therapies using novel combinatorial chemistry and genomic approaches, including ceritinib, a second-generation ALK inhibitor, osimertinib, a third-generation EGFR inhibitor, and purvalanol, a first-generation cyclin-dependent kinase-selective inhibitor.
Pathology and Epidemiology
AACR-James S. Ewing-Thelma B. Dunn Award for Outstanding Achievement in Pathology for Cancer Research:
Christopher DM Fletcher，MD
Award Ceremony: April 9, 16:00 (local time)
Named after James S. Ewing, MD, the first president of the AACR, and Thelma B. Dunn, MD, the first female president of the AACR, the award recognizes and celebrates pathologists who have made significant contributions to advancing cancer research, diagnosis, treatment, and prevention.
Christopher DM Fletcher is Professor of Pathology at Harvard Medical School, Chief Emeritus of the Division of Pathology at the Dana-Farber Cancer Institute, and Associate Director Emeritus of Anatomic Pathology at Brigham and Women's Hospital. His breakthrough discoveries have led to the molecular characterization of soft tissue tumors and provided expert insights into tumor diagnosis and clinical prognosis, thereby revolutionizing the field of cancer pathology. Christopher DM Fletcher was the first to combine soft tissue morphology with genetic damage characterization, defining more than 40 different molecular and morphological features to classify stromal tumors that have contributed to the establishment of innovative therapies for cancer patients worldwide.
AACR Award for Research Excellence in Cancer Epidemiology and Prevention:
Timothy R. Rebbeck，PhD
Award Ceremony: April 9, 15:00 (local time)
Timothy R. Rebbeck is a Fellow of the American Association for Cancer Research and is currently Professor of Cancer Prevention at the Zhonghe Chen School of Public Health, Director of the Zhu Family Center for Global Cancer Prevention, and Director of the Center for Global Health Equity at the Dana-Farber Cancer Institute.
He was recognized for his pioneering contributions to optimizing cancer prevention standards and reducing cancer mortality in clinical practice by describing the role of BRCA1/2 gene mutations in high-risk breast and ovarian cancer populations, as well as quantifying prostate cancer risk in the global African diaspora using clinical patient data, comprehensive genotypes, and tumor biomarkers.
Editor in charge: Sheep
*The medical community strives to be professional and reliable in its published content, but does not promise the accuracy of the content.